DiaMedica Therapeutics Reports Q3 GAAP EPS of -$0.21 in Line with Expectations
DiaMedica Therapeutics (DMAC) has released its third-quarter financial results, reporting a GAAP earnings per share (EPS) of -$0.21, which aligned with market expectations. The company's liquidity position saw a notable decrease during the period. As of September 30, 2026, cash, cash equivalents, and short-term investments totaled $34.9 million, down from $59.9 million at the end of 2025. Additionally, working capital decreased to $28.0 million from a previous high of $55.5 million, as current liabilities rose to $7.5 million.
Tickers: $DMAC
Topics: cash position earnings report GAAP EPS working capital
Read the full article at Seeking Alpha
Part of the story DiaMedica Therapeutics Reports Q3 GAAP EPS of -$0.21 in Line with Expectations (2 articles)